Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Dosing our first patient in the clinical trial is an exciting milestone," said Dr. Josefin-Beate (Josi) Holz, CMO of Prokarium. "It translates our scientific promises into practical advancements, as we strive to transform the treatment paradigm for patients with NMIBC."
Kristen Albright, CEO of Prokarium, remarked, "We are grateful to the patients and urologists involved in the PARADIGM-1 clinical trial. This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
LONDON -- Businesswire -- Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).
The study is being conducted at multiple clinical sites across the United States and will initially evaluate the safety of a single intravesical administration of their investigational immunotherapy, ZH9, in NMIBC patients. The study will further investigate and characterize clinical efficacy of the ZH9 treatment regimen in pre-planned expansion cohorts under the same IND.
“Dosing our first patient in the clinical trial is an exciting milestone,” said Dr. Josefin-Beate (Josi) Holz, CMO of Prokarium. “It translates our scientific promises into practical advancements, as we strive to transform the treatment paradigm for patients with NMIBC.”
Dr. Daniel Zainfeld, Urology San Antonio, commented, “We are excited to have dosed our first patient in Prokarium’s PARADIGM-1 study. The trial provides us the opportunity to explore an innovative treatment approach for our NMIBC patients who are facing significant gaps in available effective treatment options.”
Kristen Albright, CEO of Prokarium, remarked, “We are grateful to the patients and urologists involved in the PARADIGM-1 clinical trial. This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology.”
About Prokarium
Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology. Prokarium’s lead program, currently advancing in US clinical trials for bladder cancer, is a single-dose therapy redesigning the treatment paradigm for patients. The Company’s Living Cures platform aims to transform precision medicine into off-the-shelf programmable therapeutics, promising a new class of immunotherapies with a goal of equitable access. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
About ZH9
ZH9, a proprietary bacterial immunotherapy under investigation in the PARADIGM-1 clinical trial (NCT06181266) in the United States, seeks to redesign the treatment paradigm for non-muscle invasive bladder cancer patients through a single-dose intravesical induction regimen.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207504370/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Prokarium
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 하이엔드 복합 리조트 SK핀크스, 포도호텔 등 신입·경력 하반기 정기채용 실시 - 뉴스와이어
- 텔레다인, 산업 자동화 및 검사용 차세대 AI 기반 스마트 카메라 전격 출시 - 뉴스와이어
- 큐리언트, 임시주주총회 성료… 동구바이오제약과 협력 강화로 새로운 도약 기대 - 뉴스와이어
- 바노바기, 기미 잡티 케어 ‘알파 래디언스 라인’ 확장… 인기 제품군 화해 쇼핑 공식 입점 - 뉴
- 로큰롤 명예의 전당, 2024 헌액식 축하무대 빛낼 스페셜 게스트 라인업 공개 - 뉴스와이어
- 세계녹색경제정상회의 2024, 기후 회복력 강화와 지속가능한 발전 촉진 위한 녹색 금융의 중대한
- 청년 취업 성공 비결은 인턴십 경험… 전문가가 추천하는 5가지 핵심 팁 - 뉴스와이어
- 다락원, 신간 ‘이 책 한권이면 나도 사장’ 출판기념회 성황리 개최 - 뉴스와이어
- 창작 국악그룹 협동조합 연희나래 독아지 ‘제29회 순천 낙안읍성 민속문화축제’ 참여 - 뉴스와
- 가천대 원격평생교육원, 학점은행제 사회복지사 2급 자격증 총장 명의 학위패키지 개설 - 뉴스와